SillaJen, Inc. (KOSDAQ:215600)
South Korea
· Delayed Price · Currency is KRW 2,200.00
+5.00 (0.23%)
Apr 1, 2025, 3:30 PM KST
SillaJen Revenue
In the year 2024, SillaJen had annual revenue of 3.93B KRW, down -0.33%. SillaJen had revenue of 1.53B in the quarter ending December 31, 2024, a decrease of -230.45%.
Revenue
3.93B
Revenue Growth
-0.33%
P/S Ratio
67.55
Revenue / Employee
91.32M
Employees
37
Market Cap
302.04B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.93B | -12.90M | -0.33% |
| Dec 31, 2023 | 3.94B | -1.07B | -21.42% |
| Dec 31, 2022 | 5.01B | 4.76B | 1,870.95% |
| Dec 31, 2021 | 254.36M | -1.42B | -84.77% |
| Dec 31, 2020 | 1.67B | -7.40B | -81.59% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,547.32B |
| Celltrion | 3,557.30B |
| ALTEOGEN | 102.85B |
| Yuhan | 2,067.79B |
| SK Biopharmaceuticals | 547.60B |
| HLB Co., Ltd. | 51.92B |
| Sam Chun Dang Pharm. | 210.92B |
| PharmaResearch | 350.12B |